ReviewACS omega2025
Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Generalizable Strategies for the Synthesis of Cereblon-Recruiting PROTAC Prodrugs.Angewandte Chemie (International ed. in English) · 2026Article
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- Induced proximity-based therapeutics for advanced prostate cancer.npj drug discovery · 2026Review
- Precision-Engineered PROTACs: Integrating Physical and Chemical Strategies for Targeted Cancer Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- E3 ubiquitin ligases in neurodegenerative diseases.Military Medical Research · 2026Review
- Next-Generation Proteolysis-Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation.Drug development research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
At present, PROTACs have garnered significant attention as a burgeoning therapeutic approach. Relying on endogenous E3 ubiquitin ligases, PROTACs achieve the catalytic degradation of target proteins through a cyclic catalytic mechanism. Its event-driven pharmacology has resolved the problem of "undruggable" targets in diseases, such as cancers, greatly expanding the field of drug development. Nevertheless, the clinical implementation of PROTACs is constrained by their systemic toxicity and suboptimal bioavailability. In response, PROTAC prodrugs have emerged as a strategy to enable spatiotemporally controlled protein degradation in specific target tissues. This approach leverages diverse stimuliincluding light, enzymes, and immune system componentsto achieve precise activation and localized action. Meanwhile, to address the issues of druggability, some systems for PROTAC delivery have also been developed, such as polymers, conjugates, albumin, and liposomes. Overall, this review discusses the activation methods and optimization strategies of PROTACs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.